NAKA vs WELL vs VTR vs OPRX vs OHI vs JPM vs KO

For growth investors, Welltower Inc.

(WELL) is the stronger pick with 35. 8% revenue growth year-over-year, versus -33. 0% for Nakamoto Inc. (NAKA). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 3x forward), making it the more compelling value choice. Analysts rate Nakamoto Inc. (NAKA) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus Ventas, Inc. at 154. 6x. On forward P/E, OptimizeRx Corporation is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus The Coca-Cola Company's 2. 21x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Welltower Inc.

(WELL) delivered a total return of +178. 2%, compared to -96. 3% for Nakamoto Inc. (NAKA). Over 10 years, the gap is even starker: JPM returned +475. 6% versus NAKA's -96. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Omega Healthcare Investors, Inc.

(OHI) is the lower-risk stock at -0. 21β versus Nakamoto Inc. 's 2. 88β — meaning NAKA is approximately -1476% more volatile than OHI relative to the S&P 500. On balance sheet safety, OptimizeRx Corporation (OPRX) carries a lower debt/equity ratio of 20% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Welltower Inc.

(WELL) is pulling ahead at 35. 8% versus -33. 0% for Nakamoto Inc. (NAKA). On earnings-per-share growth, the picture is similar: Ventas, Inc. grew EPS 184. 2% year-over-year, compared to -1452. 2% for Nakamoto Inc.. Over a 3-year CAGR, WELL leads at 22. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Omega Healthcare Investors, Inc.

(OHI) is the more profitable company, earning 49. 3% net margin versus -28. 7% for Nakamoto Inc. — meaning it keeps 49. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OHI leads at 62. 6% versus -108. 2% for NAKA. At the gross margin level — before operating expenses — OPRX leads at 63. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus The Coca-Cola Company's 2. 21x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, OptimizeRx Corporation (OPRX) trades at 5. 6x forward P/E versus 133. 8x for Ventas, Inc. — 128. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPRX: 219. 5% to $17. 00.

In this comparison, OHI (5.

6% yield), KO (2. 5% yield), VTR (2. 2% yield), JPM (1. 9% yield), WELL (1. 3% yield) pay a dividend. NAKA, OPRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Omega Healthcare Investors, Inc.

(OHI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 21), 5. 6% yield, +117. 7% 10Y return). Nakamoto Inc. (NAKA) carries a higher beta of 2. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OHI: +117. 7%, NAKA: -96. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NAKA (Financial Services) and WELL (Real Estate) and VTR (Real Estate) and OPRX (Healthcare) and OHI (Real Estate) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NAKA is a small-cap quality compounder stock; WELL is a mid-cap high-growth stock; VTR is a mid-cap high-growth stock; OPRX is a small-cap high-growth stock; OHI is a mid-cap income-oriented stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. WELL, VTR, OHI, JPM, KO pay a dividend while NAKA, OPRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.